These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28674348)

  • 1. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
    Shimoyama T; Chinda D; Sawada Y; Komai K; Chiba H; Saito Y; Sasaki Y; Matsuzaka M; Fukuda S
    Intern Med; 2017; 56(13):1621-1627. PubMed ID: 28674348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
    Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
    World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
    Lee VW; Chau TS; Chan AK; Lee KK; Waye MM; Ling TK; Chan FK
    J Clin Pharm Ther; 2010 Jun; 35(3):343-50. PubMed ID: 20831535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
    Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
    Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
    Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
    Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
    Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
    J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
    Wu IC; Wu DC; Hsu PI; Lu CY; Yu FJ; Wang TE; Chang WH; Chen JJ; Kuo FC; Wu JY; Wang WM; Bair MJ
    Helicobacter; 2007 Dec; 12(6):633-7. PubMed ID: 18001406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
    Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori.
    Lin YA; Wang H; Gu ZJ; Wang WJ; Zeng XY; Du YL; Ying SS; Zhang BH
    Med Sci Monit; 2017 Jun; 23():2701-2707. PubMed ID: 28577017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan.
    Tai WC; Wu IT; Wang HM; Huang PY; Yao CC; Wu CK; Yang SC; Liang CM; Hsu PI; Chuah SK
    J Microbiol Immunol Infect; 2024 Aug; 57(4):601-608. PubMed ID: 38461114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β].
    Bakulina NV; Maev IV; Savilova IV; Bakulin IG; Il'chishina TA; Zagorodnikova KA; Murzina AA; Andreev DN
    Ter Arkh; 2019 Aug; 91(8):34-40. PubMed ID: 32598752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esomeprazole- or rabeprazole-based triple therapy eradicated
    Okimoto T; Mizukami K; Ogawa R; Okamoto K; Shuto M; Fukuda K; Kodama M; Murakami K
    J Clin Biochem Nutr; 2016 Sep; 59(2):149-153. PubMed ID: 27698544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
    Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
    Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
    Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
    He XX; Zhao YH; Hao YT
    Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.